Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab extension in pediatric eosinophilic esophagitis
NCT00635089Phase 3Completed
- Sponsor
- Ception Therapeutics
- Start
- Jul 2008
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of reslizumab in eosinophilic esophagitis (EoE), sponsored by Ception Therapeutics. Started Jul 2008; status: completed.
02
Drugs
reslizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT00635089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635089.